BridgeBio Pharma
BBIO
BBIO
75 hedge funds and large institutions have $2.22B invested in BridgeBio Pharma in 2019 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 18 increasing their positions, 15 reducing their positions, and 18 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
75
Holders Change
+14
Holders Change %
+22.95%
% of All Funds
1.65%
Holding in Top 10
5
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-16.67%
% of All Funds
0.11%
New
33
Increased
18
Reduced
15
Closed
18
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
+$43.7M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$32.3M |
| 3 |
BlackRock
New York
|
+$30.5M |
| 4 |
TCM
TimesSquare Capital Management
New York
|
+$8.34M |
| 5 |
State Street
Boston,
Massachusetts
|
+$7.55M |
Top Sellers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$8.18M |
| 2 |
Fidelity International
Hamilton,
Bermuda
|
-$7.81M |
| 3 |
Millennium Management
New York
|
-$7.35M |
| 4 |
JPMorgan Chase & Co
New York
|
-$7.05M |
| 5 |
SM
SCGE Management
Menlo Park,
California
|
-$3.7M |
